
Connect Biopharma Holdings Limited
$2.63
+0.4100 (18.47%)
Latest News
Connect Biopharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 19, 2026 09:00 AM
Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for 2026
Jan 12, 2026 08:00 AM
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference
Nov 24, 2025 09:00 AM
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Nov 12, 2025 09:00 AM
Connect Biopharma Presents Data Supporting Rademikibart at the European Respiratory Society Congress 2025
Sep 29, 2025 09:00 AM
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
Sep 04, 2025 08:00 AM
Connect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on Nasdaq
Sep 03, 2025 08:00 AM
Connect Biopharma to Present at Two Upcoming Investor Conferences in September
Aug 27, 2025 09:00 AM
Connect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program Nationwide
Aug 14, 2025 08:00 AM
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 13, 2025 09:00 AM
Sign Up For CNTB Email News Alerts
Disclosure
RedChip Companies, Inc. research reports, company profiles, and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that RedChip Companies Inc. is an investor relations firm hired by certain companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles, or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the Ontario Securities Commission (“OSC”) at www.osc.gov.on.ca.
Connect BioPharma (CNTB) is a client of RedChip Companies. CNTB agreed to pay RedChip Companies, Inc. a $12,500 monthly cash fee, beginning in March 2025, for six month of investor awareness services. CNTB also agreed to pay RedChip a $50,000 fee for a 10-day national TV ad campaign aired weekdays from March 17 through March 28, 2025, a $75,000 fee for a 10-day national TV ad campaign aired weekdays from May 5 through May 16, 2025, and a $75,000 fee for a 10-day national TV ad campaign aired weekdays from July 14 through July 25, 2025.
Investor awareness services and programs are designed to help small-cap companies communicate their investment characteristics. RedChip investor awareness services include the preparation of a research profile(s), multimedia marketing, and other awareness services.